Skip to main content
. 2017 Jan 26;25(2):285–293. doi: 10.3727/096504016X14732523471442

Figure 5.

Figure 5

CMTM3 inhibits the tumorigenicity in vivo. HepG2-CMTM3 cells or HepG2-vector cells were introduced subcutaneously to Balb/c nude mice. (A) The tumor volumes were calculated in each group every 5 days. (B) The tumors were weighed at 25 days after inoculation. These data are from three independent experiments and presented as the mean ± SD. *p < 0.05.